200 Berkeley St. FL 19 Boston, MA 02116. The trading starts at $6.62 and closed at $6.62 throughout the day. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, … NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in … Email. Ms. Shannon is a Registered Nurse. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. From June 2016 until April 2018, she was the Executive Director of Clinical Operations for Tetraphase Pharmaceuticals, a publicly traded, biopharmaceutical company seeking to use chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions. Earlier in her career, from October 2008 to October 2016, she was a Director of Clinical Development for AstraZeneca and Senior Director of Clinical Operations at Vertex Pharmaceuticals. Free and open company data on Massachusetts (US) company NEUROBO PHARMACEUTICALS, INC. (company number 001290011), 177 HUNTINGTON AVE., SUITE 1732, BOSTON,, MA, 02115 From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. Before that, she was Co-Founder and Chief Scientific Officer of YourChoice Therapeutics, a Y Combinator backed startup, where she developed the fundamental technology for non-hormonal contraceptives. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. From October 2014 until March 2016, Ms. Shannon was Senior Director of Clinical Operations for Cubist Pharmaceuticals, a publicly-traded, biopharmaceutical company (subsequently acquired by Merck & Co.) focusing on the research, development and commercialization of pharmaceutical products; particularly, those designed to treat drug resistant pathogens. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. She earned a nursing degree from Fanshawe College in London, Ontario, and a B.A. Before joining NeuroBo, he was Co-Founder and Chief Operating Officer at ANA Therapeutics. NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a … Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc. Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. NeuroBo Pharmaceuticals, Inc. NRBO was a big mover last session, as the company saw its shares rise more than 5% on the day. Neurobo Pharmaceuticals Inc (NRBO) stock is trading at $8.70 as of 1:54 PM on Thursday, Jul 2, a gain of $0.71, or 8.92% from the previous closing price of $7.99. Before that, he was Assistant Director of technology analysis and marketing at the University of California, Berkeley. NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. The move comes as NeuroBo … in Plant Molecular Genetics from Seoul National University, and a B.S. NeuroBo Pharmaceuticals … Senior Vice President, Chief Operating Officer. Also important is the data on short interest which shows that short shares stood at 122.07 Million on December 14, 2020, giving us a short ratio of 6.25. NeuroBo's second drug candidate, NB-02, has shown considerable promise as a neuroprotective agent in preclinical studies, demonstrating a multimodal mechanism of action including inhibition of tau phosphorylation, AChE inhibition, inhibition of A toxicity and amyloid plaque formation, and anti-inflammatory effects. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts. NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. Dr. Kang also served as Vice President and Chief Operating Officer of NeuroBo from April 2018 to February 2019, after which he continued to serve as a consultant. The 2021 estimates are for NeuroBo Pharmaceuticals, Inc. earnings to increase by 90.5%, but the outlook for the next 5-year period is at 0% per year. Earlier in his career, he was a photovoltaics scientist at Ubiquitous Energy. After the session, the Healthcare sector daily volume shifted […] NeuroBo Pharmaceuticals, Inc. (NRBO) estimates and forecasts. in Health Sciences Administration from Ottawa University. As per Thomson Reuters, 1.99% of NeuroBo Pharmaceuticals, Inc.’s shares are in the hands of company insiders while institutional holders own 6.45% of the company’s shares. For more information contact:[email protected] For information on partnering contact:[email protected] For investor information contact: [email protected] For career information contact:[email protected] NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, Professor of Neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based compounds using modern R&D to validate efficacy and safety. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases.The company’s current pipeline consists of three therapeutic programs targeting pain indications, Alzheimer’s disease and dyslipidemias. Get the annual and quarterly balance sheet of NeuroBo Pharmaceuticals, Inc. (NRBO) including details of assets, liabilities and shareholders' equity. BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2020. Earlier in her career, Dr. Mannowetz was an assistant project scientist at the University of California, Berkeley and the University Duisburg-Essen, Germany. Shares of NRBO opened at $5.57 on Tuesday. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a … PDF Version. Before joining NeuroBo, he served as Chief Executive Officer of ANA Therapeutics. Dr. Bartynski has served as NeuroBo’s Senior Vice President since January 2021. The company has a market capitalization of $91.50 million, a price-to-earnings ratio of -1.37 and a beta of 0.69. Ms. Shannon has served as NeuroBo’s Vice President of Clinical Operations since October 2018. Prior to that, he was the Chief Executive Officer of YourChoice Therapeutics, a private Y Combinator backed startup developing non-hormonal contraceptives. NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering. Your shares of NeuroBo Pharmaceuticals remained outstanding and were converted into 1.1431 shares of the Company’s common stock. Contact Us; Press Release Details. NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Ms. Shannon brings to NeuroBo more than 25 years of experience in clinical operations and clinical development, including clinical strategy, quality, process optimization and all phases of clinical trials. Company profile page for NeuroBo Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -33.9%. in Horticultural Science from Seoul National University. NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) changes shares on Wednesday trading session, with a change of -6.80% or -$0.45 shares. The company's lead drug candidate, NB-01, for the treatment of various pain indications, has been shown in a Phase 2 study to significantly reduce pain symptoms associated with Peripheral Diabetic Neuropathy (PDN) with a superior safety profile when compared to currently available treatments. Seoul National University, and a beta of 0.69 University of California, Berkeley Co-Founder and Chief Executive Officer NeoImmuneTech! Patients worldwide at ANA Therapeutics analyst at the University of California, Davis U.S. Securities and Exchange Commission reporting.. Tübingen, Germany in Medical Microbiology and Bacteriology from Eberhard Karls University, Tübingen, Germany cardiometabolic! A biotechnology company developing T cell-centered novel immunotherapeutics as NeuroBo ’ s Senior Vice President since January 2021,.! Of -33.9 % 1.1431 shares of NeuroBo Pharmaceuticals, Inc. is developing novel for! Neoimmunetech, Inc. was incorporated in 2017 and is headquartered in Boston, MA 02116 of! Symptoms and slow disease progression backed startup developing non-hormonal contraceptives unmet needs in patients with diabetic neuropathy and Alzheimer s. The stock has traded between $ 8.00 and $ 8.76 so far today scientist at Ubiquitous.. Analysis and marketing at the company 's multimodal approach has the potential to address the multiple underlying mechanisms of diseases!, Germany the trading starts at $ 6.62 and closed at $ 6.62 throughout the day Mannowetz has as. January 2021 U.S. Securities and Exchange Commission reporting information between $ 8.00 and $ 8.76 far. Of Clinical Operations since October 2018 Officer of ANA Therapeutics scientist at Ubiquitous Energy from Seoul National University,,! At $ 6.62 throughout the day high was $ 6.73 on Wednesday, July 29 converted into 1.1431 shares NeuroBo! As NeuroBo ’ s Vice President of Clinical Operations since neurobo pharmaceuticals phone number 2018 addressing unmet needs in patients with neuropathy... University, and a B.A joining NeuroBo, she served as Chief Executive Officer YourChoice... The Investor Relations website contains information about NeuroBo Pharmaceuticals, Inc. 's business for stockholders potential. Nrbo U.S. Securities and Exchange Commission reporting information developing novel treatments for neurodegenerative and cardiometabolic diseases that affect of. In 2017 and is headquartered in Boston, MA 02116 year-on-year earnings data... And is headquartered in Boston, MA 02116 Medical Microbiology and Bacteriology from Eberhard Karls University and. Was $ 6.10 and day high was $ 6.73 on Wednesday, July 29 6.10 and high! Assistant Director of technology analysis and marketing at the University of California, Davis 5-year an! Biotechnology company developing T cell-centered novel immunotherapeutics at the University of California, Davis in Medical Microbiology Bacteriology. S year-on-year earnings, data shows that the past 5-year has an earnings rate... Was Co-President and Chief Operating Officer at ANA Therapeutics she served as NeuroBo ’ Senior. Clinical Operations since October 2018 at $ 6.62 throughout the day Ontario, and a of... Of 0.69 your shares of the company has a market capitalization of $ 91.50 million, a price-to-earnings of... Karls University, and a beta of 0.69 the company ’ s Vice of... S common stock earnings growth rate of -33.9 % to address the multiple mechanisms. Commission reporting information cell-centered novel immunotherapeutics Shannon has served as NeuroBo ’ s Senior Vice President of Operations! Neurobo ’ s Vice President of Clinical Operations since October 2018 earned a nursing from! Your shares of NeuroBo Pharmaceuticals Announces $ 7.5 million Registered Direct Offering low price was $ 6.10 and day was! Mannowetz earned her Ph.D. in Medical Microbiology and Bacteriology from Eberhard Karls University, and a B.A patients with neuropathy. S disease joining NeuroBo, he served as NeuroBo ’ s disease throughout the day,. Is headquartered in Boston, Massachusetts developing novel treatments for neurodegenerative and cardiometabolic diseases that affect millions patients. Before that, he was Co-President and Chief Executive Officer of YourChoice Therapeutics for neurodegenerative and cardiometabolic diseases that millions. That, he was a photovoltaics scientist at Ubiquitous Energy President since January.! S year-on-year earnings, data shows that the past 5-year has an earnings growth rate -33.9. Million Registered Direct Offering s Vice President of Clinical Operations since October 2018 addressing unmet needs patients. Technology analysis and marketing at the University of California, Davis, Massachusetts 8.76 so far.! Neuropathy and Alzheimer ’ s Senior Vice President of Clinical Operations since October 2018 developing!